DermTech

DermTech, Inc. is a molecular diagnostic company based in La Jolla, California, focused on developing and marketing innovative non-invasive diagnostic tests for skin cancer and related conditions. The company’s flagship product, the Pigmented Lesion Assay (PLA), is a gene expression test designed to rule out melanoma and eliminate the need for surgical biopsies of atypical pigmented lesions. Additionally, DermTech offers the Nevome test, which serves as an adjunctive reflex test for the PLA, along with adhesive skin sample collection kits and gene expression assays targeting various inflammatory pathways. The company is also working on diagnostic products for non-melanoma skin cancer and risk assessment. DermTech primarily markets its products to pathology and oncology practitioners, leveraging advanced qPCR assays that utilize non-invasive adhesive tape biopsy methods to analyze RNA expression levels in skin samples.